Patents
Ungulates produced by nuclear transfer of G1 cells
Patent Number: 7,304,204This patent is one of Ian Wilmut's family of patents covering various aspects of the cloning procedure. In this particular patent cloning of an ungulate (e.g. pigs, horses, sheep, or goats) is covered through the use of nuclear transfer in which the donor nucleus is in the G1 phase of the cell cycle and the recipient oocyte is blocked in the metaphase II phase and enucleated.
Inventors: Campbell; Keith Henry Stockman (Midlothian, GB), Wilmut; Ian (Midlothian, GB)
Assignee: Roslin Institute (Midlothian, GB)
Date of First Priority Issue: Thursday August 31st, 1995
Methods for assisting recovery of damaged brain and spinal cord using arrays of X-Ray microplanar beams
Patent Number: 7,305,064It has always been the belief of StemCellPatents.com that the future of stem cell therapeutics is not only in the development and use of stem cell types, but the integration of stem cells with other modalities to attain synergy. For example, while FDA/EMEA development of cellular product candidates takes years and hundreds of millions of dollars, the same, or very similar stem cell products are...
Inventors: Dilmanian; F. Avraham (Yaphank, NY), McDonald, III; John W. (Baltimore, MD)
Assignee: Brookhaven Science Associates, LLC (Upton, NY)
Date of First Priority Issue: Thursday February 10th, 2005
Method for purifying pluri-differentiated mesenchymal progenitor cells
Patent Number: 7,303,769This patent covers the extraction/purification of a type of mesenchymal stem cell. Specifically the invention claims removing macrophages from a Dexter culture, fractionating cells, and collecting from the factionated cells a stem cell population. The fractionation procedure may be performed by percoll gradient (a type of density gradient). The stem cells that are purified are called...
Inventors: Seshi; Beerelli (Tampa, FL)
Assignee: University of South Florida (Tampa, FL)
Date of First Priority Issue: Monday June 5th, 2000
Peptides that stimulate cell survival and axon regeneration
Patent Number: 7,304,129This patent covers the composition of matter for several peptides as well as their utility for "stimulating the survival of, or neurite outgrowth in, cultured mammalian neuron, oligodendrocyte or fibroblast cells." The peptides are derived from the fibronectin domain of NCAM and have the ability to bind and activate the FGF2 receptor. Additionally, the inventors have demonstrated ability...
Inventors: Saffell; Jane Louise (London, GB)
Assignee: Imperial Innovations Limited (London, GB); King's College Innovations (London, GB)
Date of First Priority Issue: Friday June 16th, 2000
Mammalian myeloid progenitor cell subsets
Patent Number: 7,300,760This patent covers a method of extracting or substantially purifying for cells having myeloid stem cell potential. The method covers the selection of cells that are Thy-1 negative, interleukin-7 negative, and lineage negative. By lineage negative the claim means the cells not expressing CD2; CD3; CD4; CD7; CD8; CD10; CD11b; CD14; CD19; CD20; CD56; and glycophorin A (GPA).
Inventors: Weissman; Irving L. (Redwood City, CA), Traver; David Jeffrey (West Roxbury, MA), Akashi; Koichi (Boston, MA), Manz; Markus Gabriel (Palo Alto, CA), Miyamoto; Toshihiro (Menlo Park, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Date of First Priority Issue: Tuesday June 29th, 1999
Scaffold and method for implanting cells
Patent Number: 7,299,805As more and more becomes known regarding stem cell extraction, differentiation, and manipulation, the value of scaffolding and delivery technologies will increase. The current patent addresses a new way of inserting stem cells into a host through the use of scaffolds derived from bacterial biofilm. Essentially the patent covers various polysaccharide biofilms for generation of structures that...
Inventors: Bonutti; Peter M. (Effingham, IL)
Assignee: MarcTec, LLC (Effingham, IL)
Date of First Priority Issue: Sunday July 7th, 2002
Method of testing myelotoxicity with the use of flow cytometer
Patent Number: 7,300,763Development of chemotherapeutic drugs is dependent on proper animal preclinical toxicology systems. These systems are very important since chemotherapeutic drugs usually have a very small margin in which tumor toxicity is achieved but healthy tissue is not completely destroyed. One of the first body systems to go during chemotherapeutic dose escalation is the hematopoietic system. This is why...
Inventors: Miura; Daishiro (Tokyo, JP), Ogata; Shoko (Tokyo, JP), Koike; Yukiya (Tokyo, JP)
Assignee: Teijin Limited (Osaka, JP)
Date of First Priority Issue: Friday June 8th, 2001
Use of osteopontin for the treatment and/or prevention of neurologic diseases
Patent Number: 7,297,099Osteopontin is a cytokine molecule that is involved in tumor metastasis and various immune functions. In the current invention, osteopontin is used to treat chemotherapy-induced neurotoxicity. This is essentially a next step from the previous work of the same inventors who previously patented the use of osteopontin for...
Inventors: Boschert; Ursula (Troinex, CH), Feger; Georg (Thoiry, FR), Selvaraju; Raghuram (Vandoeuvres, CH), Bernasconi; Lilia (Perly, CH), Papoian; Ruben (Cincinnati, OH)
Assignee: Laboratoires Serono SA (Coinsins, Vaud, CH)
Date of First Priority Issue: Thursday May 17th, 2001
Mammalian common lymphoid progenitor cell
Patent Number: 7,297,329This patent covers "transplantation of lymphopoietic activity" into a mammal by the transfer of cells possessing "common lymphoid progenitor" activity. Essentially the claims state that this "common lymphoid progenitor" activity correlates with cells that are express low levels of c-kit, high levels of the alpha receptor for interleukin-7 and are lineage negative. This makes sense that it...
Inventors: Akashi; Koichi (Chestnut Hill, MA), Weissman; Irving L. (Redwood City, CA), Kondo; Motonari (Redwood City, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Date of First Priority Issue: Friday August 15th, 1997
Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
Patent Number: 7,297,540In the area of stem cell biology many say that "microenvironment is everything". In the current patent, the inventors take this literally. They developed a method of taking tissue, decellularizing it, and using it as a scaffold for new stem cells to grow on. The invention covers such an approach for the generation of "mini-organs" or "micro-organs" including, small subsets of skin, lung...
Inventors: Mitrani; Eduardo N. (Jerusalem, IL)
Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL)
Date of First Priority Issue: Monday January 15th, 2001